EE65 Budget Impact of Zanubrutinib for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia in the United States

Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.317
https://www.valueinhealthjournal.com/article/S1098-3015(22)02521-9/fulltext
Title : EE65 Budget Impact of Zanubrutinib for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia in the United States
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02521-9&doi=10.1016/j.jval.2022.09.317
First page :
Section Title :
Open access? : No
Section Order : 12122
Categories :
Tags :
Regions :
ViH Article Tags :